Loading news...
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Car-Mart (CRMT) To Contact Him Directly To Discuss Their Options
BROAD ARROW TO HOST PREVIEW OF SELECT CARS SET FOR UPCOMING CALENDAR AT ROLAND-GARROS STADIUM FROM 27 TO 30 JANUARY 2026 | HIGHLIGHTS OF THE GLOBAL ICONS: ONLINE PREVIEW INCLUDE MICHAEL SCHUMACHER'S 1992 BENETTON B192 FORMULA ONE CAR, 1971 LAMBORGHINI MIURA P400 S, 1967 FERRARI 275 GTS, AND IMPORTANT MOTORSPORT MEMORABILIA | EX-ROLAND GARROS TYPE 18 BUGATTI, ‘BLACK BESS' WILL BE DISPLAYED AT ROLAND-GARROS STADIUM PREVIEW COURTESY OF THE LOUWMAN MUSEUM | BROAD ARROW STAND AT RÉTROMOBILE TO PREVIEW EARLY HIGHLIGHTS FOR CONCORSO D'ELEGANZA VILLA D'ESTE SALE: BUGATTI TYPE 43 ROADSTER AND FERRARI F40 BROAD ARROW TO HOST PREVIEW OF SELECT CARS SET FOR UPCOMING CALENDAR AT ROLAND-GARROS STADIUM FROM 27 TO 30 JANUARY 2026 | HIGHLIGHTS OF THE GLOBAL ICONS: ONLINE PREVIEW INCLUDE MICHAEL SCHUMACHER'S 1992 BENETTON B192 FORMULA ONE CAR, 1971 LAMBORGHINI MIURA P400 S, 1967 FERRARI 275 GTS, AND IMPORTANT MOTORSPORT MEMORABILIA | EX-ROLAND GARROS TYPE 18 BUGATTI, ‘BLACK BESS' WILL BE DISPLAYED AT ROLAND-GARROS STADIUM PREVIEW COURTESY OF THE LOUWMAN MUSEUM | BROAD ARROW STAND AT RÉTROMOBILE TO PREVIEW EARLY HIGHLIGHTS FOR CONCORSO D'ELEGANZA VILLA D'ESTE SALE: BUGATTI TYPE 43 ROADSTER AND FERRARI F40
PARSIPPANY, N.J., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its fourth quarter 2025 results after the market close on Wednesday, February 18th, 2026, and to host a conference call for institutional investors to discuss these results on Thursday, February 19th, 2026, at 8:30 a.m.
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today outlined 2026 as a program-defining year for allogeneic CAR T, with multiple first-half clinical readouts expected to test, and potentially validate, whether off-the-shelf CAR T can be delivered at biologic-like scale, in real-world settings, across oncology and autoimmune disease.
EXTREMELY RARE OPPORTUNITY TO ACQUIRE THE F1 CAR IN WHICH MICHAEL SCHUMACHER WON HIS FIRST GRAND PRIX IN BELGIUM IN 1992 | BENETTON B192-05 USED EXCLUSIVELY BY SCHUMACHER IN FIVE GRANDS PRIX DURING 1992 F1 SEASON | THE LAST RACE-WINNING F1 CAR TO USE A MANUAL GEARBOX | CAR WAS RETAINED BY BENETTON BEFORE BECOMING PART OF THE RENAULT CLASSIC COLLECTION AND HAS NEVER BEFORE BEEN OFFERED FOR PUBLIC SALE | PART OF THE BROAD ARROW GLOBAL ICONS: EUROPE ONLINE SALE OPEN FROM 23-30 JANUARY 2026 EXTREMELY RARE OPPORTUNITY TO ACQUIRE THE F1 CAR IN WHICH MICHAEL SCHUMACHER WON HIS FIRST GRAND PRIX IN BELGIUM IN 1992 | BENETTON B192-05 USED EXCLUSIVELY BY SCHUMACHER IN FIVE GRANDS PRIX DURING 1992 F1 SEASON | THE LAST RACE-WINNING F1 CAR TO USE A MANUAL GEARBOX | CAR WAS RETAINED BY BENETTON BEFORE BECOMING PART OF THE RENAULT CLASSIC COLLECTION AND HAS NEVER BEFORE BEEN OFFERED FOR PUBLIC SALE | PART OF THE BROAD ARROW GLOBAL ICONS: EUROPE ONLINE SALE OPEN FROM 23-30 JANUARY 2026
CAR's rental-led growth shines as Q4 2025 revenues and earnings are set to rise, backed by fleet efficiency, tech upgrades and the premium Avis First launch.
Avis Budget Group, Inc. (NASDAQ: CAR - Get Free Report) has been assigned an average recommendation of "Reduce" from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating
Avis Budget Group, Inc. (NASDAQ: CAR - Get Free Report) saw unusually large options trading on Wednesday. Traders bought 43,035 put options on the company. This is an increase of approximately 727% compared to the average volume of 5,205 put options. Avis Budget Group Trading Down 5.2% Avis Budget Group stock opened at $127.89 on Thursday.
Texas Permanent School Fund Corp trimmed its stake in shares of Avis Budget Group, Inc. (NASDAQ: CAR) by 81.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,044 shares of the business services provider's stock after selling 56,651 shares during the
Caxton Associates LLP purchased a new position in Avis Budget Group, Inc. (NASDAQ: CAR) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm purchased 27,377 shares of the business services provider's stock, valued at approximately $4,628,000. Caxton Associates LLP owned about 0.08% of Avis Budget Group
Valvoline CEO Lori Flees discusses the used car boom, decreased interest in electric vehicles and more on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #theclamancountdown #foxbusiness #valvoline #ev #electricvehicles #usedcars #autos #cars #market #economy #business #transportation #energy #trump #donaldtrump
Toronto-based Maple Rock Capital Partners sold 415,584 shares of Avis Budget Group in the third quarter. The move marked a full exit for Maple Rock, effectively eliminating a position previously valued at $70.3 million.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL).
Franklin Resources Inc. acquired a new stake in Avis Budget Group, Inc. (NASDAQ: CAR) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 37,421 shares of the business services provider's stock, valued at approximately $6,326,000. Franklin Resources Inc. owned approximately 0.11% of Avis Budget Group
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma.
NOVEL THREE-PART ONLINE AUCTION TO INCLUDE EUROPE AND UK-BASED COLLECTOR CARS ALONGSIDE MOTORSPORT MEMORABILIA | HIGHLY ORIGINAL 1971 LAMBORGHINI MIURA P400 S LEADS EARLY COLLECTOR CAR HIGHLIGHTS | LIVE PREVIEW OPPORTUNITIES ACROSS MULTIPLE COUNTRIES TO BE ANNOUNCED | BIDDING OPENS JANUARY 23, 2026 NOVEL THREE-PART ONLINE AUCTION TO INCLUDE EUROPE AND UK-BASED COLLECTOR CARS ALONGSIDE MOTORSPORT MEMORABILIA | HIGHLY ORIGINAL 1971 LAMBORGHINI MIURA P400 S LEADS EARLY COLLECTOR CAR HIGHLIGHTS | LIVE PREVIEW OPPORTUNITIES ACROSS MULTIPLE COUNTRIES TO BE ANNOUNCED | BIDDING OPENS JANUARY 23, 2026
All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T program Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR ⍺ Antagonist, Phase 3-ready) and TPST-1495 (Dual Ep2/4 Antagonist, Phase 2 start expected near term) The anticipated preclosing equity financing and an investment commitment from Factor Bioscience is expected to extend Tempest's runway to mid 2027 and through potentially significant milestones Plan to proceed with execution of globally approved protocol for amezalpat in first-line HCC subject to additional resources or partnerships Matt Angel, Ph.D. to assume role of President and CEO and Stephen Brady to assume role of Chairman of the board of directors upon closing of the acquisition BRISBANE, Calif.
SAN JOSE, Calif. , Nov. 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) approved "liraltagene autoleucel" for the non-proprietary name of the Company's novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
/PRNewswire/ -- I-CAR (the Inter-Industry Conference on Auto Collision Repair) proudly recognized the outstanding achievements of this year's industry award